期刊
JOURNAL OF HEPATOLOGY
卷 56, 期 6, 页码 1330-1335出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2012.01.008
关键词
Hepatocellular carcinoma; Chemoembolization; Drug eluting beads (DEB); Safety; Survival
资金
- Sumitomo
- Pharmexa
- Eisai
- Biocompatibles
- Biolliance
- Bayer Schering
- Lilly
- Novartis
- Arqule
- Angiodynamics
- Kowa
- Imclone
- Bayer Pharmaceutical
- Bristol Myers Squibb
- Instituto de Salud Carlos III [PI 08/0146, FI09/00510]
- BBVA foundation
- University of Barcelona [APIF RD63/2006]
- US National Institutes of Diabetes and Digestive and Kidney Diseases [1R01DK076986-01]
- European Commission [259744]
- Spanish National Health Institute [SAF-2010-16055]
- ICREA Funding Source: Custom
Background & Aims: Transarterial chemoembolisation (TACE) improves survival of properly selected patients with hepatocellular carcinoma (HCC). Drug eluting beads (DEB) provide a calibrated and homogenous procedure while increasing efficacy. Outcome data applying this technology is lacking, and this is instrumental for clinical decision-making and for trial design. We evaluated the survival of HCC patients treated with DEB-TACE following a strict selection (preserved liver function, absence of symptoms, extrahepatic spread or vascular invasion). Methods: We registered baseline characteristics, the development of treatment-related adverse events, and the overall survival of all HCC patients treated by DEB-TACE from February 2004 to June 2010. Results: One hundred and four patients were treated with DEB-TACE. All but one were cirrhotic, 62.5% HCV+, 95% Child-Pugh A, 41 BCLC-A and 63 BCLC-B. Causes of DEB-TACE treatment in BCLC-A patients were: 35 unfeasible ablation, and six post-treatment recurrences. After a median follow-up of 24.5 months, 38 patients had died, two patients had received transplantation and 24 had received sorafenib because of untreatable tumour progression. Median survival of the cohort was 48.6 months (95% CI: 36.9-61.2), while it was 54.2 months in BCLC stage A and 47.7 months in stage B. Median survival after censoring follow-up at time of transplant/sorafenib was 47.7 (95% CI: 37.9-57.5) months. Conclusions: These data validate the safety of DEB-TACE and show that the survival expectancy applying current selection criteria and technique is better than that previously reported. A 50% survival at 4 years should be considered when suggesting treatment for patients fitting into controversial scenarios such as expanded criteria for transplantation/resection for multifocal HCC. (C) 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据